Obesity Drug Stocks: Where to Invest Now
Let’s delve into the exciting world of obesity drug stocks. These pharmaceutical companies are at the forefront of developing treatments for…
Tag: Eli Lilly
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
Researchers from the Evernorth Research Institute in St. Louis conducted a study to understand the prevalence of discontinuation of glucagon-like peptide 1 (GLP-1)…
Ozempic and GLP-1s are Reshaping the Travel Industry
These groundbreaking weight loss medications have far-reaching implications, impacting not only individual health but also travel experiences and businesses. 🌎✈️…
GLP-1 Medications: Celebrities Share Their Experiences
In recent years, GLP-1 medications have become a beacon of hope for many struggling with weight management. These drugs, including…
Debunking the Most Common Myths About Weight Loss Drugs
As medications like Ozempic, Wegovy and Mounjaro see soaring popularity for treating obesity, a number of myths and misconceptions about…
The Struggle to Keep Weight Off After Stopping Ozempic and Other GLP-1 Drugs
The Struggle to Keep Weight Off After Stopping Ozempic and Other GLP-1 Drugs While medications in the GLP-1 class like…
The Unexpected Side Effects of GLP-1 Drugs Like Ozempic
While medications like Ozempic (semaglutide) and Wegovy have gained massive popularity for their remarkable weight loss and diabetes management abilities,…
‘Ozempic Babies’ Concerns? Study Finds High GLP-1 Drug Use Among Young Women
A new study has revealed that over 75% of young adults aged 16-44 taking medications like Ozempic, Wegovy and Mounjaro…
Weighing the Costs and Side Effects of Popular Weight Loss Drugs
There are high costs and potential side effects of the new generation of weight loss medications like semaglutide (Wegovy) and…
